

Attorney Docket No.:  
Inventors:  
Serial No.:  
Filing Date:  
Page 2

ABLE-0014  
Ormerod and Winfield  
09/530,375  
July 7, 2000



RECEIVED  
JAN 04 2002  
TECH CENTER 1600/2900

In the Claims:

Please cancel ~~claim~~ 27.

Please amend the claims as follows:

24. (amended) A topical formulation for the treatment of a dermatological condition which comprises a macrocyclic lactone antibiotic, an immunosuppressive macrolide wherein the macrolide is sirolimus, FK506 or SDZ ASM 981 and a permeation modulator which are present in relative amounts such that when a therapeutic amount is applied to the skin a minimal systemic effect is produced.

**REMARKS**

Claims 24-26 and 28-39 are pending in the instant application. Claims 24-39 have been rejected. Claim 27 has been canceled. Claim 24 has been amended. Reconsideration is respectfully requested in light of these amendments and the following remarks.

**I. Rejection of Claims Under 35 U.S.C. 112, First Paragraph**

Claims 24-39 have been rejected under 35 U.S.C. §112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to